218 related articles for article (PubMed ID: 35202890)
1. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
Jang JH
Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
[TBL] [Abstract][Full Text] [Related]
4. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.
Eilts SK; Pfeil JM; Poschkamp B; Krohne TU; Eter N; Barth T; Guthoff R; Lagrèze W; Grundel M; Bründer MC; Busch M; Kalpathy-Cramer J; Chiang MF; Chan RVP; Coyner AS; Ostmo S; Campbell JP; Stahl A;
JAMA Netw Open; 2023 Jan; 6(1):e2251512. PubMed ID: 36656578
[TBL] [Abstract][Full Text] [Related]
7. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
9. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
[TBL] [Abstract][Full Text] [Related]
13. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
Sahinoglu-Keskek N; Akkoyun I; Torer B
Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
[TBL] [Abstract][Full Text] [Related]
15. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
[TBL] [Abstract][Full Text] [Related]
16. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
17. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.
Fidler M; Fleck BW; Stahl A; Marlow N; Chastain JE; Li J; Lepore D; Reynolds JD; Chiang MF; Fielder AR;
Transl Vis Sci Technol; 2020 Jul; 9(8):43. PubMed ID: 32855889
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]